Friday, March 20, 2020

08:15–08:30  Welcome

SESSION I – The genomic and epigenomic landscape of CLL and clinical consequences
Chair (s): TBA

08:30-08:45  Genetic predisposition
Jennifer Brown (Boston)
08:45-08:50  Discussion

08:50-09:05  Genetic landscape
Cathy Wu (Boston)
09:05-09:10  Discussion

09:10-09:25  Ibrutinib
Jennifer Woyach (Colombus)
09:25-09:30  Discussion

09:30-09:45  Epigenetic landscape
Chris Oakes (Columbus)
09:45-09:50  Discussion

09:50-10:05  Risk stratification: future perspective
Panagiotis Baliakas (Uppsala)
(complex karyotype? NOTCH1?)
10:05-10:10  Discussion

10:10-10:40  Panel discussion

10:40-11:10  Coffee Break

SESSION II – The role of BCR activation and signalling for CLL
Chair (s): TBA

11:10-11:25  BCR isotypes/autonomous signalling
Hassan Jumaa (Ulm)
11:25-11:30  Discussion

11:30-11:45  The latest news on stereotypes
Kostas Stamatopoulos (Thessaloniki)
11:45-11:50  Discussion

11:50-12:05  Novel BCR targets
Andrew Steele (Southampton)
12:05-12:10  Discussion
12:10-12:25 Next generation BTK inhibitors (covalent/non-covalent?) Constantine Tam (Melbourne)
12:25-12:30 Discussion

12:30-12:37 Short talk TBA
12:37-12:40 Discussion

12:40-13:10 Panel discussion

13:10-14:50 Lunch

13:30-14:30 Possible slot for a satellite symposium

SESSION III – Therapeutic options for CLL
Chair(s): TBA

15:00-15:15 Ibrutinib for everybody Jennifer Woyach (Columbus)
15:15-15:20 Discussion

15:20-15:35 Ibrutinib for a small subgroups only Florence Cymbalista (Paris)
15:35-15:40 Discussion

15:40-15:55 MURANO and MRD John Seymour (Melbourne)
15:55-16:00 Discussion

16:00-16:15 CLL14 update Kirsten Fischer (Cologne)
16:15-16:20 Discussion

16:20-16:27 Short talk TBA
16:27-16:30 Discussion

16:30-17:00 Panel discussion

17:00-17:30 Coffee break

SESSION IV – Long term follow up of clinical trials versus real world data (Outside Clinical Trials data-OCT)
Chair(s): TBA

17:30-17:45 Ibrutinib trials Alessandra Tedeschi (Milan)
17:45-17:50 Discussion

17:50-18:05 Ibrutinib real world George Follows (Cambridge)
18:05-18:10 Discussion

18:10-18:25 Venetoclax trials Matthew Davids (Boston)
18:25-18:30 Discussion

18:30-18:45 Venetoclax / PI3K real world Anthony Mato (New York)
18:45-18:50 Discussion

18:50-18:57 Short talk TBA
18:57-19:00 Discussion

19:00-19:30 Panel discussion

19:30 Get together and poster walks (stand up cocktails and buffet dinner for all)
09:00-10:00  Possible slot for a satellite symposium

09:00-10:00  3 Simultaneous Meet the Expert sessions (non-clinical)

1. Prognostic and predictive markers  
   Barbara Eichhorst (Cologne)
2. Resistance to ibrutinib: what to do  
   Jennifer Brown (Boston)
3. First line therapy: continuous or time limited treatment?  
   Michael Hallek (Cologne)

10:00-10:30  Coffee break

SESSION V – The increasing role of the leukaemic microenvironment  
Chair (s): TBA

10:30-10:45  Role of stromal cells  
Andrea Brendolan (Milan)
10:45-10:50  Discussion

10:50-11:05  Tissue recirculation of leukaemic cells  
Silvia Deaglio (Turin)
11:05-11:20  Discussion

11:20-11:35  Role of T cells  
Arnon Kater (Amsterdam)
11:35-11:40  Discussion

11:40-11:55  Immunomodulatory effects of kinase inhibitors  
Adrian Wiestner (Bethesda)
11:55-12:00  Discussion

12:00-12:07  Short talk  
TBA
12:07-12:10  Discussion

12:10-12:40  Panel discussion

12:40-13:30  Lunch

13:20-14:20  Possible slot for a satellite symposium

SESSION VI – Therapeutic options 2: The use of cellular and non-cellular immunotherapies in CLL  
Chair (s): TBA

14:30-14:45  Next generation PI3K inhibitors  
Peter Hillmen (Leeds)
14:45-14:50  Discussion

14:50-15:05  Novel inhibitors at preclinical level  
Alexey Danilov (Portland)  
(MCL1 & CDK inhibitors)
15:05-15:10  Discussion

15:10-15:25  Optimizing the use of BH3 Mimetics in CLL  
Eric Eldering (Amsterdam)
15:25-15:30  Discussion

15:30-15:45  CAR-T cells  
David Maloney (Seattle)
15:45-15:50  Discussion

15:50-16:05  Allo-transplant  
Peter Dreger (Heidelberg)
16:05-16:10  Discussion
16:10-16:40  Panel discussion

16:40-17:10  Coffee break

SESSION VII – Efficacy through safety
Chair (s): TBA

17:10-17:25  Cardiologist  Javid Moslehi (Nashville)
17:25-17:30  Discussion

17:30-17:45  Dermatologist  Nicole LeBoeuf (Boston)
17:45-17:50  Discussion

17:50-18:05  Infectious diseases  Pierluigi Viale (Bologna)
18:05-18:10  Discussion

18:10-18:25  Gastroenterology  Stefano Fagiuoli (Bergamo)
18:25-18:30  Discussion

18:30-19:00  Panel discussion

Free evening

Sunday, March 22, 2020

07:30-08:30  3 Simultaneous Breakfast Meet the Expert Sessions (clinical)

1.  Treatment of relapsed CLL  Paolo Ghia (Milan)
2.  Management of novel drugs side effect  Carol Moreno (Barcelona)
3.  MRD assessment  Andy Rawstron (Leeds)*

SESSION VIII – Clonal heterogeneity, clonal evolution and mechanisms of drug resistance
Chair (s): TBA

08:40-08:55  Clonal evolution  Davide Rossi (Bellinzona)
08:55-09:00  Discussion

09:00-09:15  PI3K  Jennifer Brown (Boston)
09:15-09:20  Discussion

09:20-09:35  Venetoclax  John Seymour (Melbourne)
09:35-09:40  Discussion

09:40-09:47  Short talk  TBA
09:47-09:50  Discussion

09:50-10:20  Panel discussion

10:20-10:50  Coffee break
SESSION IX – Contrasting therapeutic concepts:
Chair (s): TBA

10:50-11:05  MRD as a dynamic endpoint  
11:05-11:10  Discussion  
Peter Hillmen (Leeds)

11:10-11:25  Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction in lymphoid malignancies including CLL  
11:25-11:30  Discussion  
David M. Kurtz (Stanford)

11:30-11:45  Sequential vs combination treatments  
11:45-11:50  Discussion  
Bill Wierda (Houston)

11:50-12:05  Time limited vs continuous treatments  
12:05-12:10  Discussion  
Barbara Eichhorst (Cologne)

12:10-12:40  Panel discussion

12:40-12:50  Closing Remarks

MEETING CLOSURE

*pending confirmation